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Abstract
Background: The search for biomarkers in Parkinson’s disease (PD) is crucial to identify the disease early and
monitor the effectiveness of neuroprotective therapies. We aim to assess whether a gene signature could be
detected in blood from early/mild PD patients that could support the diagnosis of early PD, focusing on genes
found particularly altered in the substantia nigra of sporadic PD.
Results: The transcriptional expression of seven selected genes was examined in blood samples from 62 early stage
PD patients and 64 healthy age-matched controls. Stepwise multivariate logistic regression analysis identified five
genes as optimal predictors of PD: p19 S-phase kinase-associated protein 1A (odds ratio [OR] 0.73; 95% confidence
interval [CI] 0.60–0.90), huntingtin interacting protein-2 (OR 1.32; CI 1.08–1.61), aldehyde dehydrogenase family 1
subfamily A1 (OR 0.86; 95% CI 0.75–0.99), 19 S proteasomal protein PSMC4 (OR 0.73; 95% CI 0.60–0.89) and heat
shock 70-kDa protein 8 (OR 1.39; 95% CI 1.14–1.70). At a 0.5 cut-off the gene panel yielded a sensitivity and
specificity in detecting PD of 90.3 and 89.1 respectively and the area under the receiving operating curve (ROC
AUC) was 0.96.
The performance of the five-gene classifier on the de novo PD individuals alone composing the early PD cohort
(n = 38), resulted in a similar ROC with an AUC of 0.95, indicating the stability of the model and also, that patient
medication had no significant effect on the predictive probability (PP) of the classifier for PD risk. The predictive
ability of the model was validated in an independent cohort of 30 patients at advanced stage of PD, classifying
correctly all cases as PD (100% sensitivity). Notably, the nominal average value of the PP for PD (0.95 (SD = 0.09)) in
this cohort was higher than that of the early PD group (0.83 (SD = 0.22)), suggesting a potential for the model to
assess disease severity. Lastly, the gene panel fully discriminated between PD and Alzheimer’s disease (n = 29).
Conclusions: The findings provide evidence on the ability of a five-gene panel to diagnose early/mild PD, with a
possible diagnostic value for detection of asymptomatic PD before overt expression of the disorder.
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Background
Currently, the diagnosis of Parkinson’s disease (PD) is
based mainly on clinical criteria [1]. In addition the evalu-
ation of the clinical status and evolution of PD are based
on examination of symptoms, utilizing structured scoring
systems (Unified Parkinson’s Disease Rating Scale,
(UPDRS) [2], Short Parkinson Evaluation Scale, (SPES),
SCales for Outcomes in PArkinson’s diseases– (SCOPA)
[3,4] and the Hoehn and Yahr (H&Y) staging scale [5]. Al-
though PD can be accurately diagnosed in patients with a
typical presentation and positive response to levodopa with
a sensitivity of 93% [6], differential diagnosis from other
entities presenting parkinsonism (e.g. essential tremor,
progressive supranuclear palsy (PSP), multisystem atrophy
(MSA), corticobasal degeneration (CBD)) may be challen-
ging. Imaging studies using positron emission tomography
(PET) with [18 F]-Dopa, single photon emission tomog-
raphy (SPECT) with [123I]-β-CIT or diffusion-weighted
MRI could improve differential diagnosis of parkinsonism
[7-9], but cost-effectiveness remains a problem.
Furthermore, these tools do not provide a specific and
sensitive enough PD diagnosis [10]. The discovery of
mutations linked to familial PD and the implementation of
microarray-based gene expression profiling during the past
decade, has provided additional clues for the pathophysi-
ology of sporadic PD as well as potential molecular targets
that may be of relevance to the disease [11-16]. Our previ-
ous gene expression study conducted in post-mortem sub-
stantia nigra (SN) obtained from sporadic PD patients
identified a cluster of genes that were most differentially
expressed in sporadic parkinsonian SN, by a factor of ≥1.5,
compared to non-diseases controls [11]. The transcripts
were mainly related to DA transmission and metabolism,
and protein handling/degradation mechanisms previously
known to be involved in the pathophysiology of the dis-
ease. Examples include SKP1A (p19, S phase kinase-asso-
ciated protein 1A), a component of the largest class of E3
ubiquitin ligases, SCF (Skp1, Cullin 1, a substrate recogniz-
ing F-box protein and Rbx1) [17,18], HSPA8 (heat shock
70-kDa protein 8, encoding chaperone Hsc-70) [19], and
19 S proteasomal protein PSMC4/S6b/TBP7, whose levels
were decreased in PD. Also, aldehyde dehydrogenase fam-
ily 1, subfamily A1 (ALDH1A1) involved in the degrad-
ation of aldehyde derivatives of DA, and vesicular
monoamine member 2 (VMAT2) were down-regulated.
Recent studies have shown the feasibility of studying
peripheral (cerebrospinal fluid (CSF), blood and urine) sig-
natures or biomarkers for potential diagnosis and early de-
tection of PD [20] such as alpha-synuclein and DJ-1
protein in the CSF [21-23]. Serum uric acid appears to be
the first molecular factor linked to a decreased risk of PD
[24,25] and to inversely correlate with clinical and radio-
graphic progression of typical PD [26]. Furthermore, in-
creasing evidence indicates that peripheral tissue shares
significant protein/gene expression similarities to inaccess-
ible central nervous system (CNS) tissues [27,28] and thus
may offer valuable surrogate markers for neuropsychiatric
disorders. For instance, a recent large serum proteomic
study with psychiatric patients has identified a number of
proteins belonging to pathways previously shown to be
involved in the pathophysiology of either depression or
schizophrenia, such as growth factors, cytokines and neu-
rotrophins [29]. In a microarray gene profiling study with
blood PD tissue, it was demonstrated a panel of genes
associated with PD risk, some of them involved in patho-
biologically relevant disease processes of the ubiquitin–
proteasome pathway system (UPS), mitochondrial func-
tion, and apoptosis [27]. More recently, a genome-wide
pathway meta-analysis (meta-GSEA) with PD tissues has
particularly identified a set of genes controlling cellular
bioenergetics and mitochondria biogenesis that were
shared by both brain and blood [30]. Using a similar, but
less comprehensive approach of integrating openly avail-
able and new PD microarray data, a panel of genes was
identified to be commonly expressed in brain and blood
samples [31]. These findings suggest that blood and brain
neuronal cells might have a common regulatory mechan-
ism for gene expression.
The seven genes chosen for the study form part of the
core of 20 gene transcripts most significantly altered in
PDSN from sporadic PD patients [11]. Here we analyze
their expression in peripheral blood from early PD
patients to identify a signature that could support the
diagnosis of the disease.
Results
Identification of a PD risk gene signature
A five-gene panel was found that optimally discriminates
early PD from controls based on stepwise multivariate
logistic regression analysis of seven genes that were
found significantly altered in sporadic PD SN tissue [11]
(ALDH1A1, PSMC4, SKP1A, HSPA8, c-src Tryosine
Kinase [CSK], huntingtin interacting protein 2/ubiquitin-
conjugating enzyme E2K [HIP2] and Egl nine homolog 1
[EGLN1]). The composition of the PD cohort comprised
mild/early stage PD (38 de novo and 24 medicated PD,
H&Y=1.40 (SD= 0.56)). As shown in Table 1 SKP1A,
HIP2, ALDH1A1, PSMC4 and HSPA8, were classified as
optimal predictors for PD risk. Negative regression coef-
ficients (B) indicate an inverse relationship between tran-
script expression and risk for PD. Thus, the negative
values of ALDH1A1, PSMC4 and SKP1A suggest that
these genes possibly decrease the risk for the occurrence
of PD with OR values of 0.86, 0.73 and 0.73 respectively,
whereas HSPA8 and HIP2 significantly increase the risk
for PD, with OR values of 1.39 and 1.32, respectively.
The predicted probability (PP) for PD in a tested individ-
ual was calculated by the equation described in the
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Materials and Methods and the diagnostic performance
of the gene cluster was assessed by a receiver operating
characteristic curve (ROC), showing high sensitivity and
specificity for the early stage PD group versus healthy
controls at various cut-offs (Figure 1, blue line), with an
area under the curve (AUC) of 0.96. The performance of
the classifier on the 38 de novo, non medicated PD indi-
viduals alone from the early PD cohort, resulted in a
similar ROC with an AUC of 0.95, indicating the stability
of the classifier model (Figure 1, red line) and suggesting
that medication does not influence the predictive value
of the genetic signature. In support, no significant differ-
ence was observed between the PP average value of the
non-medicated, de-novo PD cohort (0.81 (SD= 0.20))
and that of the early medicated population (0.87 (SD=
0.25); t-test, p = 0.354).
The distribution of the PP values of the early/mild PD
cohort vs those of healthy (control) subjects is depicted
in Figure 2A. To better represent the true predictive
value of the model, we selected a cut-off of 0.5 beyond
which the subjects were considered as having PD. At this
cut-off point we were able to distinguish between PD
individuals and healthy controls with sensitivity and spe-
cificity values of 90.3% and 89.1% respectively.
Demographic analysis revealed no significant difference
in age between the early PD group and control group (t
test, p = 0.382; see Table 2 for patients details). When age
was introduced as a possible explanatory variable within
the regression model which included the gene expression
variables, it had no impact on the PP of the model for
PD. Regarding gender, although the proportion of males
was significantly higher in the early PD group, a two-way
ANOVA, with gender (male/female) and group (control/
PD) as variables, revealed that the differential gene ex-
pression resulted from the group variable only
(p< 0.001), being independent of gender (p = 0.522) or
gender/group interaction (p = 0.346).
Validation of specificity and sensitivity of the gene risk
panel
To validate the diagnostic value of the PD gene panel, a
separate cohort of 30 PD patients at advanced disease
stage and 29 patients with Alzheimer’s disease (AD) were
tested with the logistic classification model obtained
from the early PD-healthy control samples. The gene
cluster positively classified all 30 cases as PD (100% sen-
sitivity) and discriminated PD from AD with 100% speci-
ficity (all 29 cases were classified as non-PD), thus
supporting the diagnostic value of the molecular signa-
ture for detecting PD (Figure 2A). Notably, the nominal
average value of the PP for PD in late- stage cohort (0.95
(SD=0.09); H&Y: 3.07 (SD=0.81)) was higher than that of
the early PD group (0.83 (SD=0.22); H&Y: 1.40 (SD=
0.56)), suggesting a potential for the model to assess dis-
ease severity. The performance of the classifier across the
entire data set is depicted in Figure 2B. 86 out of 93 indivi-
duals that ranked above a PP of 0.5 are PD. 86 out of 92
individuals that ranked below a PP of 0.5 are controls.
Relative transcript expression in the different cohorts
Figure 3 shows the differential transcription pattern of the
individual five genes composing the panel, in the four
cohorts of subjects: healthy control, early stage PD,
Figure 1 The receiver operating characteristic curve (ROC) of
the logistic regression model for discriminating between early
PD and control. The blue line depicts integrative specificity and
sensitivity for the PP derived from five variables (SKP1A, HIP2,
ALDH1A1, PSMC4 and HSPA8 transcriptional expression levels,
AUC= 0.96) of the early/mild PD vs healthy control subject cohorts.
At a cut-off point of 0.5 it was possible to distinguish between PD
individuals and healthy controls with sensitivity and specificity values
of 90.3% and 89.1% respectively. The red line shows the
performance of the classifier on the 38 de novo, non medicated PD
individuals alone from the early PD cohort, which resulted in a
similar ROC with an AUC of 0.95, indicating the stability of the
logistic model.
Table 1 Variables in the predicted probability equation
B P
value
OR 95%C.I. for OR
Lower Upper
L_ SKP1 −0.313 0.003 0.731 0.595 0.898
L_ HIP2 0.274 0.008 1.315 1.076 1.608
L_ALDH1A1 −0.148 0.030 0.862 0.754 0.986
L_ PSMC4 −0.318 0.002 0.727 0.595 0.889
L_ HSPA8 0.330 0.001 1.391 1.139 1.699
L_ Natural logarithm.
B_ Regression coefficient. Negative values indicate an inverse relationship
between transcript expression and risk for PD and the opposite for positive values.
OR_odds ratio.
C.I._Confidence Interval.
Given that L_ and not raw ratios were used in logistic regression analysis,
L_values were multiplied by 10 to avoid skewed OR values.
Molochnikov et al. Molecular Neurodegeneration 2012, 7:26 Page 3 of 10
http://www.jnrbm.com/content/7/1/26
advanced stage and AD. Prominent transcript level reduc-
tions in ALDH1A1, PSMC4 and SKP1A and a significant
elevation in HSPA8 were seen in the PD groups, compared
to healthy controls, as revealed by one-way ANOVA. On
the other hand, no significant gene alterations were
encountered in HIP2 in early PD compared to control,
whereas a clear increase was seen in advanced PD stage.
A different expression pattern was seen in the AD group,
supporting the specificity of the gene changes to PD.
The correlative analysis of the expression levels of all
the tested transcripts in the control cohort, revealed a
significant association between SKP1A, HIP2, ALDH1A1
and PSMC4 (Table 3). SKP1A showed a weaker but sig-
nificant correlation with two additional transcripts,
HSPA8 and EGLN1. In contrast to the findings in the
control group, the association of SKP1A with the other
transcripts was disrupted in early PD, suggesting a pos-
sible functional connection between the panel genes.
Discussion
The results of this study support our hypothesis that there
are blood gene biomarkers that can distinguish early PD
patients from normal control subjects. Notably, 38 out of
the 62 Parkinson cases in the mild/early cohort were de
novo and so, not treated with any antiparkinsonism drug
when the blood samples were obtained while the rest were
collected during the first year of medication. This suggests
that the genetic signature could be an early diagnostic
marker for PD. In support, the classifier model performed
equally well in early stage de novo PD samples, producing
a similar ROC AUC value to that obtained with the entire
early PD cohort (de novo and medicated), indicating that
patient medication had no significant effect on the PP of
the classifier for PD risk and that the model is stable
throughout the two PD groups. Supporting this concept, it
was recently shown in a population of asymptomatic
LRRK2 mutation carriers, that reduced CSF amyloid β and
Figure 2 Predictive probability (PP) for PD in early PD subjects compared to advanced PD, AD and healthy control groups. a) The
distribution of the PP values of the early/mild PD, advanced PD, AD and healthy cohorts derived from the logistic regression analysis are depicted.
The box plots represent 50% of the cases, with the median (horizontal bold line) and the 1st and 3rd quartile values (bottom and top of the box,
respectively). The bottom and top whiskers show the lowest and the highest datum within 1.5x interquartile range (IQR, the range between the
1st and 3rd quartile) from bottom and top of the box, respectively. Outliers are denoted by black dots. Beyond the cut-off of PP = 0.5 the subjects
were considered as having PD. b) The performance of the classifier across the entire data set. Blood samples are ordered by their PP for PD. 86
out of 93 individuals that ranked in the upper panel (>0.5) are PD. 86 out of 92 individuals that ranked in the lower panel (< 0.5) are controls.
PD= Parkinson’s disease. AD=Alzheimer’s disease.
Table 2 Demographics and Hoehn & Yahr scores
Diagnostic groups Control PD (total cases) PD Early Stage PD Advanced Stage AD
n 64 92 62 30 29
Age (SD) 65.9 (7.9) 65.52 (10.11) 64.5 (10.2) 67.67 (9.7) 73.0 (8.4)
Minimum Age 52 35 35 52 58
Maximum Age 82 88 88 88 87
Gender (% of males) 43.8 67.4 66.1 70.0 44.8
Hoehn & Yahr (SD) 0 1.95 (1.02) 1.40 (0.56) 3.07 (0.8) 0
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Figure 3 QRT-PCR assessment of the relative transcript expression levels in the marker panel. The box plots depict the natural logarithms
of the relative gene expression levels (calculated by dividing the QRT-PCR values by the geometric mean of the HKs ACTB, ALAS1 and GAPDH raw
quantities) for the individual five genes in blood samples of 62 early stage PD patients (Early PD; H&Y= 1.40 (SD= 0.56)), 30 PD patients at
relatively advanced stage (Advanced PD; H&Y= 3.07 (SD= 0.81)), 29 AD patients and 64 healthy age-matched subjects (Control). Outliers are
denoted by black dots. The significance was calculated by one-way ANOVA, with post-Hoc Tukey analysis. *p< 0.05 vs control; ~p< 0.05 vs early
PD. In the text, expression level changes (percentage) refer to relative gene expression levels and not to the natural logarithms.
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tau species correlated with lower striatal dopaminergic
function as determined by PET [32], suggesting that they
may serve as potential biomarkers even in asymptomatic
phases of the disease. The performance of the gene model
was validated in an independent cohort of patients at
advanced PD stage where all individuals were correctly
classified as PD, while it fully discriminated PD from a
group of individuals affected with AD (considered the
most common neurodegenerative disease). Giving that
misdiagnosis occurs normally at the initial PD stage, the
100% sensitivity obtained with the long-term PD cohort
support the feasibility of the biomarker panel to differenti-
ate with certainty between PD and non-PD. Further stud-
ies will determine the ability of the panel to differentially
diagnose idiopathic PD from patients with other forms of
Parkinsonism, such as PSP and MSA.
One main challenge in the development of biological
markers is to minimize the number of genes in the classifi-
cation model while still achieving a high classification rate.
The present biomarker signature identified a minimal set
of transcripts in blood that has a high discriminating
power to categorize the PD early group and to positively/
negatively classify the advanced PD and AD cohorts.
A model with fewer genes is likely to yield better
generalization (less number of free variables) and opti-
mization of diagnosis. We have found that five out of the
seven gene transcripts previously reported to have been
changed in sporadic PDSN [11], were found altered in
blood of mild/early PD. Our findings argue in support of
the view that changes in peripheral blood may have rele-
vance to mechanisms occurring in brain of PD patients
and indicate that at least some of the gene expression
alterations occurring in PD are not exclusive to the
brain, but are expressed also in peripheral blood tissue.
Indeed, a large proportion of the genes encoded in the
human genome have detectable levels of transcripts in
circulating blood cells [33]; When coming into contact
with brain tissue, circulating blood cells may provide in-
formation concerning the pathological environment of
the PD brain.
Gene expression correlation analysis indicates a signifi-
cant association in blood from healthy control individuals
between SKP1A and five gene transcripts: HIP2,
ALDH1A1, PSMC4, HSPA8 and EGLN1, while it was ab-
sent in early PD, suggesting a functional coordinative role
for Skp1. Skp1 takes part in the ubiquitin-proteasome/E3-
ligase SCF complex, acting in a module-like manner: Skp1
can interact with several F-box proteins, which play an in-
dispensable role in the selection of target proteins for deg-
radation [17]. Thus, a reduced activity of Skp1 may play a
role in the development of PD by impairing the timely
degradation of a wide array of proteins, promote their de-
position and affect the function of dopaminergic (DAergic)
neurons. Skp1, together with the chaperone Hsc-70
encoded by HSPA8, the proteasomal ATPase subunit
PSMC4, the EGLN1-encoded prolyl hydroxylase and the
huntingtin-interacting protein Hip2, are intimately con-
nected to processing/degradation of proteins by UPS/lyso-
somal- mediated degradation [17-19,34-37]. Further
evidence for a possible functional connection between the
panel genes is provided by our recent finding showing that
silencing SKP1A in the SN-derived murine cell line
SN4741 induced a parallel down-regulation in the tran-
scripts of ALDH1A1 and HSPA8 [38]. Aldh1 was found to
be expressed highly and specifically in DA cells of the SN
and ventral tegmental area (VTA) [39] having a role in the
neutralization of toxic aldehyde derivatives of DA [34].
These highly reactive, neurotoxic aldehydes can accumu-
late in case of decreased levels of Aldh1, as occurs in SNpc
of PD [39,40], and can promote neuronal death. The fact
that the five genes comprising the signature, as a group,
play important roles in PD neuropathology and are
Table 3 Correlations between the natural logarithms of the relative gene expression levels in the control group
HIP2 ALDH1A1 PSMC4 HSPA8 CSK EGLN1
SKP1A R= 0.440** R = 0.600** R = 0.480** R = 0.288* R =−0.217 R = 0.283*
p< 0.001 p< 0.001 p< 0.001 p = 0.021 p= 0.196 p= 0.023
HIP2 - R = 0.459** R = 0.582** R = 0.296* R =−0.265 R = 0.371*
p< 0.001 p< 0.001 p = 0.017 p= 0.112 p= 0.03
ALDH1A1 - R = 0.385** R = 0.235 R =−0.060 R = 0.299*
p = 0.002 p = 0.061 p= 0.724 p= 0.016
PSMC4 - R = 0.402** R = 0.052 R = 0.286*
p = 0.001 p= 0.761 p= 0.022
HSPA8 - R = 0.237 R = 0.185
p= 0.158 p= 0.144
CSK - R = 0.112
p= 0.508
R= Pearson correlations coefficient.
* P< 0.05; ** P< 0.01.
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significantly correlated in blood form healthy subjects, add
a biological significance to the findings.
Supporting the rationale of identifying molecular
changes in peripheral blood that may respond to the path-
ology in the brain of sporadic PD, Grunblatt et al. [41] re-
cently reported a cluster of four genes in blood tissue that
discriminated between PD and healthy controls. One of
them, ALDH1A1 was also detected in our gene signature,
independently confirming part of our results. Further sup-
port comes from Scherzer et al. [27] who demonstrated a
panel of eight genes involved in relevant PD processes
such as the UPS, mitochondrial function and apoptosis in
whole blood tissue from a heterogeneous cohort of rela-
tively early-staged PD individuals, that correlated with PD
risk. It is worth noting that despite the difference in the
study design, e.g., the use of large-scale microarrays com-
prising the whole genome, the restricted eight-gene signa-
ture included HIP2, also found by us, as a surrogate for
PD. In our study, we have performed multi-step logistic re-
gression analysis, which is commonly applied in biomarker
research. This procedure recruits in each step the most
significant gene discriminating between PD and control in
relation to the prior step, thus taking into consideration
the cumulative impact of the gene group on the PD risk.
In Scherzer’s study, the genes were individually rank-
ordered according to the absolute value of their correlation
coefficient with PD, disregarding the correlation between
their expression levels.
Another major discovery of this investigation is that the
PP values of the five-gene signature were accentuated in
patients at late PD stage, suggesting a potential for the
model to assess disease severity. One relevant point is what
could be the biological meaning of this observation. It can
be conjectured that the peripheral gene transcriptional
changes may reflect evolution of pathogenic processes dur-
ing PD progression. In analogy, Shi et al. [42] have
described a panel of seven CSF proteins that could aid in
PD diagnosis and differential diagnosis. Among these, an
increase in CSF fractalkine, along with decreased Aβ1–42
levels, correlated with a higher UPDRS score in cross-sec-
tional samples and in a set of longitudinally collected PD
samples from the DATATOP study.
When examining the relative quantity of each gene indi-
vidually at the cross-sectional level, we demonstrated a
similar transcriptional pattern for SKP1A, ALDH1A,
PSMC4 and HSPA8 in the two PD cohorts compared to
normal controls or AD groups, suggesting that these tran-
scripts are altered at early stages of the disease and not
affected by disease progression. However, at this stage, we
cannot determine whether the selective elevation of HIP2
demonstrated only in PD patients at advanced stage of dis-
ease, can reflect a disease evolution. Despite the strength
of the present findings, there are some issues yet to be
addressed. At this point the cross-sectional nature of this
study does not allow making a correlation between gene ex-
pression and clinical symptoms that may point to the clin-
ical state. Longitudinal studies will establish whether the
gene panel can serve as a marker for PD risk or its progres-
sion. Although we have initially focused on seven out of the
20 gene transcripts most altered in sporadic PD brains, it is
likely that the other risk genes could be also relevant.
Conclusions
Our current pilot study demonstrated that the blood gene
model has strong predictive value for PD diagnosis and
possibly may help to identify individuals at presympto-
matic stages (patients with depression, sleep disturbances
or hyposmia or patients carrying genetic risk factors) who
are good candidates for neuroprotective treatment. Such a
biomarker will be of value for identification of a patho-
physiological subgroup of PD patients that may respond
favorably to agents targeting the mechanisms reflected by
the gene panel.
Large-scale, prospective, controlled studies, which com-
bine our methodology with quantification of CSF total/oli-
gomers of α-synuclein or/and DJ-1 and brain imaging may
be useful as a multi-modal biomarker, not only for early
diagnosis but for evaluation of disease progression.
Methods
Study population
The subjects examined gave written informed consent
according to the ethical committee of each hospital engaged
in the study. 185 individuals were enrolled for blood sample
mRNA extraction: 62 early/mild PD patients (38 de novo,
non medicated PD and 24 early PD patients within first year
of medication (Hoehn and Yahr; H&Y 1.40, SD=0.56), 30
PD patients with advanced disease (H&Y 3.07, SD=0.8), 29
patients with AD (Mini-Mental State Exam=19.0, SD=
2.73) and 64 healthy age-matched controls without per-
sonal or family history of neurodegenerative diseases. For
this multi- center, international study blood samples were
recruited from the following hospitals: the Department of
Neuroscience, University of Pisa (Italy), Hospital of Viareg-
gio (Italy), University Hospital of Würzburg (Germany),
Assaf Harofe and Rambam Medical Centers (Tel Aviv and
Haifa, Israel). PD patients that met modified United King-
dom Parkinson’s Disease Society Bank Brain clinical diag-
nostic criteria [1] were diagnosed by neurologists trained in
movement disorders. Patient data (age, gender, PD severity
score, H&Y, blood count and medication) were registered.
Patients with probable AD were recruited by the Clinic for
Psychiatry, Psychosomatic and Psychotherapy, University of
Würzburg, Assaf Harofe and Rambam Medical Centers.
The AD samples from University of Würzburg (n=10) are
part of a study published earlier [41]. All patients met
the National Institute of Neurological and Communicative
Disorders and Stroke-Alzheimer’s Disease and Related
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Disorders Association diagnostic criteria [43]. Control blood
samples consisted of healthy age- matched subjects that ac-
companied neurological patients during the visits to the
movement disorders centers. The proportion of males in
the healthy population was 43.8% with a mean age of
65.9±7.9 and in the PD group (early and advanced) was
67.4% and a mean age of 64.5±10.2 (see Table 2). Total
white blood cells count, as well as differential blood cell
counts were examined for any bias in gene expression
changes. No significant variations were observed via one-
way analysis of variance (ANOVA) between PD and healthy
control groups in all counts as shown in Additional file 1,
Table S1).
Isolation of total RNA from blood samples and quality
control
Venous blood samples were collected using PAXgene
Blood RNA System Tubes (Becton Dickinson GmbH,
Heidelberg, Germany) at the different centers and
shipped to the Eve Topf Center in Haifa for RNA extrac-
tion and real-time PCR (QRT-PCR) quantification, ex-
cept for the 10 AD sample cases from University of
Würzburg, which were shipped as lyophilized RNA in-
stead of blood tubes. The blood samples were frozen at
−80°C until processed for total RNA isolation. Both con-
trols and cases samples were processed in parallel. Total
RNA was extracted from whole blood with the PAXgene™
Blood RNA Kit 50 (PreAnalytiX, Qiagen and BD, Ger-
many). RNA quality was determined spectrophotomet-
rically by NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientific Inc, Wilmington, DE, USA) and by
using the ExperionTM Automated Electrophoresis System
(Bio-Rad Laboratories, Hercules, CA, USA). A represen-
tative test from arbitrarily selected RNA samples show-
ing the analysis of the 28 S and 18 S bands is provided in
Additional file 2. RNA samples that adhered to quality
control criteria (Additional file 1, Methods) were taken
for further analysis.
Quantitative real-time RT-PCR (QRT-PCR)
Total RNA from each blood sample was reversed tran-
scribed employing the High-Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA, USA).
QRT-PCR was performed using SYBR Green detection
chemistry, in the ABI PRISM 7000 Real-Time Sequence
Detection System (Applied Biosystems, Foster City, CA,
USA, see details in Additional file 1, Methods). Oligo-
nucleotide primers are depicted in Table 4. Gene expres-
sion values were normalized to three housekeeping genes
(Additional file 1, Methods and Table S2).
Building a risk marker profile
In order to establish a molecular risk marker for PD, a lo-
gistic regression model was built via stepwise multivariate
logistic regression analysis of the natural logarithms (ln) of
the relative gene expression for all seven genes, comparing
the PD early/mild subjects (38 de novo, non medicated PD
and 24 early PD patients) and the healthy control subjects
(64 healthy age-matched controls without personal or fam-
ily history of neurodegenerative diseases).
Step 1. The relative gene expression was calculated by
dividing the QRT-PCR values of the seven genes
by the geometric mean of the three most stable
housekeeping genes expression levels (GAPDH,
ACTB and ALAS1).
Step 2. The values were transformed to ln to enable
normal distribution.
Step 3. The model was built by progressively adding the
variables (relative gene expression) with the
Table 4 QRT-PCR oligonucleotide primers
Gene Name Acc number Symbol Catalog No.
Egl nine homolog 1 NM_022051 EGLN1 QT01021454
Heat shock 70 kDa protein 8 NM_006597, NM_153201 HSPA8 QT00030079
Proteasome (prosome, macropain) 26 S subunit, ATPase 4 NM_006503 PSMC4 QT00035511
Clathrin, light polypeptide NM_001834 CLTB QT00081872
Aldehyde Dehydrogenase 1 Family, member A NM_000689 ALDH1A1 QT00013286
S-phase kinase-associated protein 1A NM_006930 SKP1 QT00040320
Huntingtin interacting protein 2/ubiquitin-conjugating enzyme E2K NM_005339, NM_001111113 HIP2=UBE2K QT00010276
c-src Tryosine Kinase NM_004383, NM_001127190 CSK QT00999131
Housekeeping genes
Actin B NM_001101 ACTB QT00095431
Aminolevulinate, delta-, synthase 1 NM_000688, NM_199166 ALAS1 QT00073122
Glyceraldehyde-3-phosphate dehydrogenase NM_002046 GAPDH QT01192646
Peptidylprolyl isomerase A (cyclophilin A) NM_021130 PPIA QT01866137
Ribosomal protein L13A NM_012423 RPL13A QT00089915
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lowest, most significant, individual p value, one
at a time, at each step in the process until no
more predictors significant at p≤0.05 remained.
Step 4. From this model we calculated the PP for PD in
a tested individual, using the regression
coefficient values B obtained from the logistic
regression model via the following equation: eN/
(1 + eN), wherein N=−0.45+ Σi = 1-n (Bi*ln
(Gene_expi)), wherein each i in said formula
indicates a different gene i; Bi is the regression
coefficient value of said gene i; and Gene_expi is
the relative expression level of said gene i in said
individual.
Step 5. The PP values were used to construct a ROC
curve (and AUC) depicting the relationship
between sensitivity and specificity for the early/
mild PD group versus healthy controls.
Step 6. A correlation analysis between the individual
variables (gene expression levels) was performed
to ascertain that these do not highly correlate, as
this would add no further resolution to the
model. Notably, all the correlations were similar
with a maximal R value of 0.592.
Statistical analysis
To determine if the predicted risk for PD was independ-
ent of age, the main risk factor for PD, it was introduced
as a possible explanatory variable within the regression
model alongside with the gene expression variables.
Since the proportion of males was significantly higher in
the early PD group (Mann–Whitney non-parametric test,
p = 0.012), two-way ANOVA (followed by Tukey post-
hoc analysis), with gender (male/female) and group (con-
trol/PD) as independent variables was performed.
To assess whether dopamine replacement therapy may
influence the prediction for PD risk by the model t-test
analysis was applied to compare between the PP values
of non-medicated, de-novo PD cohort and those of the
early medicated population.
Comparison between the experimental groups was car-
ried out using one-way ANOVA followed by Tukey post-
hoc analysis. Correlations were evaluated via Pearson
Correlation with two tailed test of significance. All statis-
tical analyses were performed using SPSS Statistics 17.0
software (SPSS Inc., Chicago, Illinois, USA).
Additional files
Additional file 1: Table S1. Hematologic values of PD cases and
controls. Table S2. Stability ranking of the candidate reference genes,
Methods [44,45].
Additional file 2: Run Overview Report, Virtual Gel Report, Egram,
Gel Lane And Result Table Report.
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